ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Fluocinolone, hydroquinone, and tretinoin: Drug information

Fluocinolone, hydroquinone, and tretinoin: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Fluocinolone, hydroquinone, and tretinoin: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Tri-Luma
Pharmacologic Category
  • Corticosteroid, Topical;
  • Depigmenting Agent;
  • Retinoic Acid Derivative
Dosing: Adult
Melasma

Melasma: Topical: Apply a thin film once daily to affected areas until control is achieved; not indicated for use beyond 8 weeks.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Dermatologic: Erythema (41%), desquamation (38%), burning sensation of skin (18%), xeroderma (14%), pruritus (11%)

1% to 10%:

Central nervous system: Paresthesia (3%), hyperesthesia (2%)

Dermatologic: Acne vulgaris (5%), telangiectasia (3%), dyschromia (2%), skin irritation (2%), acne rosacea (1%), papule (1%), skin rash (1%), skin vesicle (1%)

Gastrointestinal: Xerostomia (1%)

<1%, postmarketing, and/or case reports (reported with one or more components): Acneiform eruption, allergic contact dermatitis, atrophic striae, Cushing's syndrome, exogenous ochronosis, folliculitis, HPA-axis suppression, hypopigmentation, miliaria, perioral dermatitis, secondary infection, skin atrophy

Contraindications

Hypersensitivity to fluocinolone, hydroquinone, tretinoin, or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.

• Dermatitis: Cutaneous hypersensitivity/contact dermatitis to individual ingredients has been reported; instruct patients to seek medical attention.

• Exogenous ochronosis: Hydroquinone may produce exogenous ochronosis (gradual blue/black darkening of skin); discontinuation is recommended.

• Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.

• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.

Concurrent drug therapy issues:

• Hormonal contraceptives: Consider changing to nonhormonal contraceptive measures in patients who may be receiving hormonal contraceptives.

Special populations:

• Pediatric: Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.

Dosage form specific issues:

• Sodium metabisulfate: Contains sodium metabisulfite; may cause hypersensitivity reactions, including anaphylaxis, in individuals with sulfite allergy.

Other warnings/precautions:

• Darker skin types: Has not been evaluated in skin types V and VI; excessive bleaching may occur in individuals with darker skin.

• Patient information: Instruct patients to avoid UV exposure, including sunlight (protective clothing and sunscreen recommended). Local irritation, dryness, and pruritus may be expected following application. Avoid contact with abraded skin, mucous membranes, eyes, nose, angles of the mouth.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Cream, External:

Tri-Luma: Fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% (30 g) [contains cetyl alcohol, methylparaben, propylparaben, sodium metabisulfite]

Generic Equivalent Available: US

No

Pricing: US

Cream (Tri-Luma External)

0.01-4-0.05% (per gram): $9.81

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Topical use only; not for oral, ophthalmic, or intravaginal use. Apply 30 minutes before bedtime. Wash face with mild cleanser; rinse and pat dry. Apply to lesion and 1/2 inch of normal-appearing skin surrounding each lesion. Rub lightly and uniformly into the skin. Do not use occlusive dressings. Avoid sun exposure; use a sunscreen with SPF 30 and wear protective clothing during the day. Moisturizers and /or cosmetics may be used during the day.

Hazardous Drugs Handling Considerations

Tretinoin is a hazardous agent (NIOSH 2024 [table 2]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Use: Labeled Indications

Melasma: Short-term treatment of moderate to severe melasma of the face

Medication Safety Issues
Pediatric patients: High-risk medication:

KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants <1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminolevulinic Acid (Systemic): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Systemic). Risk X: Avoid

Aminolevulinic Acid (Topical): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Topical). Risk C: Monitor

Methoxsalen (Systemic): Photosensitizing Agents may increase photosensitizing effects of Methoxsalen (Systemic). Risk C: Monitor

Porfimer: Photosensitizing Agents may increase photosensitizing effects of Porfimer. Risk X: Avoid

Verteporfin: Photosensitizing Agents may increase photosensitizing effects of Verteporfin. Risk C: Monitor

Food Interactions

Concurrent use with vitamin A may enhance adverse effects. Management: Avoid excessive intake of vitamin A (cod liver oil, halibut fish oil).

Reproductive Considerations

In clinical trials, women of reproductive potential were required to have a negative pregnancy test prior to treatment.

Pregnancy Considerations

Although pregnant women were excluded from the initial clinical studies, 13 pregnancies occurred during treatment. Three women gave birth to healthy babies, one pregnancy was terminated, and one ended in a miscarriage; outcomes of the remaining pregnancy are not known.

Refer to individual monographs for additional information.

Breastfeeding Considerations

It is not known if topical application results in sufficient systemic absorption to produce detectable concentrations of fluocinolone, hydroquinone, or tretinoin in breast milk.

The manufacturer recommends caution be used if administered to a breastfeeding woman. Avoid contact between breastfeeding infant and cream. Breastfeeding women were excluded from initial studies.

Monitoring Parameters

Signs/symptoms of HPA axis suppression

Mechanism of Action

Fluocinolone is a topical corticosteroid and has low to intermediate range potency (dosage-form dependent). Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Hydroquinone may interrupt melanin synthesis (tyrosine-tyrosinase pathway); reduces hyperpigmentation. Tretinoin is a derivative of vitamin A. When used topically, it modifies epithelial growth and differentiation.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Minimal

Metabolism: Hepatic for the small amount absorbed

Excretion: Urine and feces

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Tri luma;
  • (AR) Argentina: Neoblanc | Tri luma | Trimacrem plus | Trimegtante;
  • (BD) Bangladesh: Amela | Melacare | Melano | Melasin | Melatrin | Nospot | Triclean | Trimela | Triquin;
  • (BR) Brazil: Hidroquinona + tretinoina + fluocinolona acetonida | Hormoskin | Oskin | Suavicid | Tri luma | Triderm | Trinulox | Vitacid Plus;
  • (CL) Chile: Tri luma;
  • (CO) Colombia: Tri luma;
  • (DO) Dominican Republic: Tri luma;
  • (EC) Ecuador: Tri luma;
  • (EE) Estonia: Tri luma;
  • (EG) Egypt: Lasmacure | Melanofree;
  • (HK) Hong Kong: Tri luma;
  • (ID) Indonesia: Quintri | Refaquin;
  • (IN) India: Advan thf | Asm glo | Depiglare | Eukroma fc | I glownight | Inmela | Lumacip Plus | Lumaglo | Luminosa | Magnalyte | Mela3 | Melalong Plus | Melapik plus | Retop lite | Tri luma | Triglow | Triluma rd | Triolite | U b fair;
  • (JO) Jordan: Triderma;
  • (KE) Kenya: Triderma | Xtralite;
  • (KR) Korea, Republic of: Tri q | Triderma blanc | Triluma | Trilustra;
  • (KW) Kuwait: Tri luma;
  • (LT) Lithuania: Triluma;
  • (MX) Mexico: Tri luma;
  • (MY) Malaysia: Tri lucent | Tri luma;
  • (PE) Peru: Tri luma;
  • (PH) Philippines: Tri luma;
  • (PK) Pakistan: Acnocare | Bequin | C quin | Fabulas | Flutrizam | Flytro | Hyderquin Plus | Hydrocin | Hyluma | Krizma | Melakut | Novaderm | Redoquine | Siton Plus | Sunmet | Swinide | Tretilone | Tri lite | Tri melasin | Tricuma | Trisma | Troika;
  • (PR) Puerto Rico: Tri luma;
  • (PY) Paraguay: Trimegtante;
  • (QA) Qatar: Tri-Luma;
  • (SA) Saudi Arabia: Triluma;
  • (SG) Singapore: Tri luma;
  • (TH) Thailand: Tri luma;
  • (TW) Taiwan: Tri luma;
  • (UY) Uruguay: Tri luma | Trimegtante;
  • (VE) Venezuela, Bolivarian Republic of: Fluocinolona hidroquinona tretinoina | Hormoskin | Tri luma
  1. Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. J Natl Cancer Inst. 2002;94(22):1712-1718. [PubMed 12441327]
  2. Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
  3. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191. [PubMed 32265601]
  4. Ovesen JL, Sam­mons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
  5. Torok HM. A Comprehensive Review of the Long-Term and Short-Term Treatment of Melasma With a Triple Combination Cream. Am J Clin Dermatol. 2006;7(4):223-230. [PubMed 16901182]
  6. Tri-Luma (fluocinolone, hydroquinone, tretinoin) [prescribing information]. Sanford, FL: Hill Dermaceuticals Inc; February 2023.
  7. United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
Topic 8781 Version 161.0